A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer

Carcinogenesis

Volumn 23, Issue 11, 2002, Pages 1839-1849

  Sachse, Christoph ^a   Smith, Gillian ^a   Wilkie, Murray J V ^a   Barrett, Jennifer H ^b   Waxman, Robin ^c   Sullivan, Frank ^d   Forman, David ^c   Bishop, D Timothy ^b   Wolf, C Roland ^a   Barrett, Jenny ^b   Boobis, Alan R ^e   Garner, R Colin ^f   Gooderham, Nigel ^g   Lightfoot, Tracy ^f  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF YORK   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACYLTRANSFERASE; CARCINOGEN; CHEMICAL COMPOUND; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; HETEROCYCLIC AMINE; MICROSOME ENZYME; POLYCYCLIC AROMATIC HYDROCARBON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULFOTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGEN TESTING; CASE CONTROL STUDY; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIET; DNA POLYMORPHISM; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALLELES; AMINES; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CARCINOGENS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DIET; ENGLAND; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HETEROCYCLIC COMPOUNDS; HUMANS; ISOENZYMES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYCYCLIC HYDROCARBONS, AROMATIC; SULFOTRANSFERASES;

EID: 0036848540     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Parkin,D.M., Whelan,S.L., Ferlay,J., Raymond,L. and Young,J. (eds). (1997) Cancer Incidence in Five Continents. IARC Scientific Publications vol VII, 143 pp. IARC, Lyon.
2. Le Marchand,L. (1999) Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. J. Natl Cancer Inst. Monogr., 26, 101-105.
3. Bartsch,H., Nair,J. and Owen,R.W. (1999) Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis, 20, 2209-2218.
4. Giovannucci,E., Rimm,E.B., Stampfer,M.J., Colditz,G.A., Ascherio,A. and Willett,W.C. (1994) Intake of fat, meat and fibre in relation to risk of colon cancer in men. Cancer Res., 54, 2390-2397.
5. de Verdier,M., Hagman,U., Peters,R.K., Steineck,G. and Overvik,E. (1991) Meat, cooking methods and colorectal cancer: a case-referent study in Stockholm. Int. J. Cancer, 49, 520-525.
6. Nagao,M. and Sugimura,T. (1993) Carcinogenic factors in food with relevance to colon cancer development. Mutat. Res., 90, 43-51.
7. Kadlubar,F., Kaderlik,R.K., Mulder,G.J., et al. (1995) Metabolic activation and DNA adduct detection of PhIP in dogs, rats and humans in relation to urinary bladder and colon carcinogenesis. Princess Takamatsu Symp., 23, 207-213.
8. Sugimura,T. (2000) Nutrition and dietary carcinogens. Carcinogenesis, 21, 387-395.
9. Kadlubar,F.F., Butler,M.A., Kaderlik,K.R., Chou,H.C. and Lang,N.P. (1992) Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect., 98, 69-74.
10. Dennis,M.J., Massey,R.C., Cripps,G., Venn,I., Howarth,N. and Lee,G. (1991) Factors affecting the polycyclic aromatic hydrocarbon content of cereals, fats and other food products. Food Addit. Contam., 8, 517-530.
11. Sugimura,T. and Sato,S. (1983) Mutagens-carcinogens in foods. Cancer Res., 43, 2415-2421.
12. DeMarini,D.M., Shelton,M.L. and Levine,J.G. (1995) Mutation spectrum of cigarette smoke condensate in Salmonella: comparison to mutations in smoking-associated tumors. Carcinogenesis, 16, 2535-2542.
13. Boobis,A.R., Gooderham,N.J., Edwards,R.J., Murray,S., Lynch,A.M., Yadollahi-Farsani,M. and Davies,D.S. (1996) Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Arch. Toxicol., 18, 286-302.
14. Gooderham,N.J., Murray,S., Lynch,A.M., et al. (1996) Heterocyclic amines: evaluation of their role in diet associated human cancer. Br. J. Clin. Pharmacol., 42, 91-98.
15. Crofts,F.G., Sutter,T.R. and Strickland,P.T. (1998) Metabolism of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis, 19, 1969-1973.
16. Yamazoe,Y., Nagata,K., Yoshinari,K., Fujita,K., Shiraga,T. and Iwasaki,K. (1999) Sulfotransferase catalyzing sulfation of heterocyclic amines. Cancer Lett., 143, 103-107.
17. Gooderham,N.J., Murray,S., Lynch,A.M., Yadollahi-Farsani,M., Zhao,K., Boobis,A.R. and Davies,D.S. (2001) Food-derived heterocyclic amine mutagens: variable metabolism and significance to humans. Drug Metab. Dispos., 29, 529-534.
18. Shimada,T., Hayes,C.L., Yamazaki,H., Amin,S., Hecht,S.S., Guengerich,F.P. and Sutter,T.R. (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res., 56, 2979-2984.
19. Oda,Y., Aryal,P., Terashita,T., Gillam,E.M., Guengerich,F.P. and Shimada,T. (2001) Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1 and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase. Mutat. Res., 492, 81-90.
20. Yang,S.K. (1988) Stereoselectivity of cytochrome P-450 isoenzymes and epoxide hydrolase in the metabolism of polycyclic aromatic hydrocarbons. Biochem. Pharmacol., 37, 61-70.
21. Joseph,P. and Jaiswal,A.K. (1994) NAD (P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc. Natl Acad. Sci. USA, 91, 8413-8417.
22. Giovannucci,E., Stampfer,M.J., Colditz,G.A., Rimm,E.B., Trichopoulos,D., Rosner,B.A., Speizer,F.E. and Willett,W.C. (1993) Folate, methionine and alcohol intake and risk of colorectal adenoma. J. Natl Cancer Inst., 85, 875-884.
23. Giovannucci,E., Rimm,E.B., Ascherio,A., Stampfer,M.J., Colditz,G.A. and Willett,W.C. (1995) Alcohol, low-methionine-low-folate diets and risk of colon cancer in men. J. Natl Cancer Inst., 87, 265-273.
24. Chen,J., Giovannucci,E., Kelsey,K., Rimm,E.B., Stampfer,M.J., Colditz,G.A., Spiegelman,D., Willett,W.C. and Hunter,D.J. (1996) A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res., 56, 4862-4864.
25. Ulrich,C.M., Kampman,E., Bigler,J., et al. (2000) Lack of association between the C677T MTHFR polymorphism and colorectal hyperplastic polyps. Cancer Epidemiol. Biomarkers Prev., 9, 427-433.
26. Idle,J.R., Armstrong,M., Boddy,A.V, et al. (1992) The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics, 2, 246-258.
27. Wolf,C.R., Smith,C.A. and Forman,D. (1994) Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. Br. Med. Bull., 50, 718-731.
28. Vineis,P., Malats,N., Lang,M., d'Errico,A., Caporaso,N., Cuzick,J. and Bofetta,P (eds). (1999) Metabolic Polymorphisms and Susceptibility to Cancer. IARC Scientific Publications, vol 148. IARC, Lyon.
29. Kiss,I., Sandor,J., Pajkos,G., Bogner,B., Hegedus,G. and Ember,I. (2000) Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1 and glutathione-S-transferase M1 enzymes. Anticancer Res., 20, 519-522.
30. Zhong,S., Wyllie,A.H., Barnes,D., Wolf,C.R. and Spurr,N.K. (1993) Relationship between the GSTM1 polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis, 14, 1821-1824.
31. Deakin,M., Elder,J., Hendrickse,C., et al. (1996) Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis, 17, 881-884.
32. Lang,N.P., Chu,D.Z., Hunter,C.F., Kendall,D.C., Flammang,T.J. and Kadlubar,F.F. (1986) Role of aromatic amine acetyltransferase in human colorectal cancer. Arch. Surg., 121, 1259-1261.
33. Roberts-Thomson,I.C., Ryan,P., Khoo,K.K., Hart,W.J., McMichael,A.J. and Butler,R.N. (1996) Diet, acetylator phenotype and risk of colorectal neoplasia. Lancet, 347, 1372-1374.
34. Kampman,E., Slattery,M.L., Bigler,J., Leppert,M., Samowitz,W., Caan,B.J. and Potter,J.D. (1999) Meat consumption, genetic susceptibility and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol. Biomarkers Prev., 8, 15-24.
35. Nakajima,M., Yokoi,T., Mizutani,M., Shin,S., Kadlubar,F.F. and Kamataki,T. (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol. Biomarkers Prev., 3, 413-421.
36. Nakajima,M., Yokoi,T., Mizutani,M., Kinoshita,M., Funayama,M. and Kamataki,T. (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem., (Tokyo) 125, 803-808.
37. Sachse,C., Brockmöller,J., Bauer,S. and Roots,I. (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 1A2 (CYP1A2) gene tested with caffeine. Br. J. Clin. Pharmacol., 47, 445-449.
38. Huang,J.D., Guo,W.C., Lai,M.D., Guo,Y.L. and Lambert,G.H. (1999) Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab. Dispos., 27, 98-101.
39. Ketterer,B., Harris,J.M., Talaska,G., Meyer,D.J., Pemble,S.E., Taylor,J.B., Lang,N.P. and Kadlubar,F.F. (1992) The human glutathione S-transferase supergene family, its polymorphism and its effects on susceptibility to lung cancer. Environ. Health Perspect., 98, 87-94.
40. Schwarz,D., Kisselev,P., Cascorbi,I., Schunck,W.H. and Roots,I. (2001) Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis, 22, 453-459.
41. Crofts,F., Taioli,E., Trachman,J., Cosma,G.N., Currie,D., Toniolo,P. and Garte,S.J. (1994) Functional significance of different human CYP1A1 genotypes. Carcinogenesis, 15, 2961-2963.
42. Ishibe,N., Stampfer,M., Hunter,D.J., Hennekens,C. and Kelsey,K.T. (2000) A prospective study of cytochrome P450 1A1 polymorphisms and colorectal cancer risk in men. Cancer, Epidemiol. Biomarkers Prev., 9, 855-856.
43. Sivaraman,L., Leatham,M.P., Yee,J., Wilkens,L.R., Lau,A.F. and Le Marchand,L. (1994) CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res., 54, 3692-3695.
44. Cortessis,V., Siegmund,K., Chen,Q., et al. (2001) A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3 and risk of colorectal adenomas. Cancer Res., 61, 2381-2385.
45. Harrison,D.J., Hubbard,A.L., MacMillan,J., Wyllie,A.H. and Smith,C.A.D. (1999) Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br. J. Cancer, 79, 168-171.
46. Keicho,N., Emi,M., Kajita,M., Matsushita,I., Nakata,K., Azuma,A., Ohishi,N. and Kudoh,S. (2001) Overestimated frequency of a possible emphysema-susceptibility allele when microsomal epoxide hydrolase is genotyped by the conventional polymerase chain reaction-based method. J. Hum. Genet., 46, 96-98.
47. Hassett,C., Aicher,L., Sidhu,J.S. and Omiecinski,C.J. (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet., 3, 421-428.
48. Forrester,L.M., Neal,G.E., Judah,D.J., Glancey,M.J. and Wolf,C.R. (1990) Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc. Natl Acad. Sci. USA, 87, 8306-8310.
49. Yamazaki,H., Inui,Y., Yun,C.H., Guengerich,F.P. and Shimada,T. (1992) Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789-1794.
50. Tyndale,R.F. and Sellers,E.M. (2001) Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab. Dispos., 29, 548-552.
51. Chen,G.F., Tang,Y.M., Green,B., Lin,D.X., Guengerich,F.P., Daly,A.K., Caporaso,N.E. and Kadlubar,F.F. (1999) Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction. Pharmacogenetics, 9, 327-332.
52. Oscarson,M., McLellan,R.A., Gullsten,H., Agundez,J.A., Benitez,J., Rautio,A., Raunio,H., Pelkonen,O. and Ingelman-Sundberg,M. (1999) Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett., 460, 321-327.
53. Pitarque,M., von Richter,O., Oke,B., Berkkan,H., Oscarson,M. and Ingelman-Sundberg,M. (2001) Identification of a single nucleotide polymorphism in the tata box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun., 284, 455-460.
54. Brockmöller,J., Cascorbi,I., Kerb,R. and Roots,I. (1996) Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56, 3915-3925.
55. Spurr,N.K., Gough,A.C,, Chinegwundoh,F.I. and Smith,C.A. (1995) Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin. Chem., 41, 1864-1869.
56. D'Errico,A., Malats,N., Vineis,P. and Bofetta,P. (1999) Review of studies of selected metabolic polymorphisms and cancer. In: Vineis,P. et al. (eds). Metabolic Polymorphisms and Susceptibility to Cancer. IARC Scientific Publications, vol. 148, Chapter 23, pp. 323-393. IARC, Lyon.
57. Houlston,R.S. and Tomlinson,I.P.M. (2001) Polymorphisms and colorectal tumor risk. Gastroenterology, 121, 282-301.
58. Lang,N.P., Butler,M.A., Massengill,J., Lawson,M., Stotts,R.C., Hauer-Jensen,M. and Kadlubar,F.F. (1994) Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prev., 3, 675-682.
59. Welfare,M.R., Cooper,J., Bassendine,M.F. and Daly,A.K. (1997) Relationship between acetylator status, smoking and diet and colorectal cancer risk in the north-east of England. Carcinogenesis, 18, 1351-1354.
60. Chen,J., Stampfer,M.J., Hough,H.L., Garcia-Closas,M., Willett,W.C., Hennekens,C.H., Kelsey,K.T. and Hunter,D.J. (1998) A prospective study of N-acetyltransferase genotype, red meat intake and risk of colorectal cancer. Cancer Res., 58, 3307-3311.
61. Sachse,C., Chana,U., Smith,G., Lightfoot,T.J., Barrett,J., Scollay,J., Boobis,A.R., Wolf,C.R. and Gooderham,N.J. (2002) Polymorphisms of the cytochrome P450 1A2 gene (CYP1A2): frequency in colorectal cancer cases and controls, linkage disequilibrium and functional impact on caffeine metabolism. Submitted to the British Journal of Clinical Pharmacology.
62. Sprenger,R., Schlagenhaufer,R., Kerb,R., Bruhn,C., Brockmöller,J., Roots,I. and Brinkmann,U. (2000) Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics, 10, 557-565.
63. Chenevix-Trench,G., Young,J., Coggan,M. and Board,P. (1995) Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis, 16, 1655-1657.
64. Welfare,M., Adeokun,A.M., Bassendine,M.F. and Daly,A.K. (1999) Polymorphisms in GSTP1, GSTM1 and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 8, 289-292.
65. Stubbins,M.J., Harries,L.W., Smith,G., Tarbit,M.H. and Wolf,C.R. (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-439.
66. Aithal,G.P., Day,C.R, Kesteven,P.J. and Daly,A.K. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717-719.
67. Meehan,R.R., Speed,R.M., Gosden,J.R., et al. (1988) Chromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylase. Proc. Natl Acad. Sci. USA, 85, 2662-2666.
68. Bigler,J., Whitton,J., Lampe,J.W., Fosdick,L., Bostick,R.M. and Potter,J.D. (2001) CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res., 61, 3566-3569.
69. Fritsche,E., Bruning,T., Jonkmanns,C., Ko,Y., Bolt,H.M. and Abel,J. (1999) Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. Pharmacogenetics, 9, 405-408.
70. Murray,G.I., Taylor,M.C., McFadyen,M.C., McKay,J.A., Greenlee,W.F., Burke,M.D. and Melvin,W.T. (1997) Tumor-specific expression of cytochrome P450 CYP1B1 Cancer Res., 57, 3026-3031.
71. Lafuente,M.J., Casterad,X., Trias,M., Ascaso,C., Molina,R., Ballesta,A., Zheng,S., Wiencke,J.K. and Lafuente,A. (2000) NAD (P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-1819.
72. Code,E.L., Crespi,C.L., Penman,B.W., Gonzalez,F.J., Chang,T.K. and Waxman,D.J. (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity and role in procarcinogen activation. Drug Metab. Dispos., 25, 985-993.
73. Kuehl,P., Zhang,J., Lin,Y., et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet, 27, 383-391.
74. Rebbeck,T.R., Jaffe,J.M., Walker,A.H., Wein,A.J. and Malkowicz,S.B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst., 90, 1225-1229.
75. Felix,C.A., Walker,A.H., Lange,B.J., et al. (1998) Association of CYP3A4 genotype with treatment-related leukaemia Proc. Natl Acad Sci. USA, 95, 13176-13181.
76. Westlind,A., Lofberg,L., Tindberg,N. Andersson,T.B. and Ingelman-Sundberg,M. (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun., 259, 201-205.
77. Lang,T., Klein,K., Fischer,J., Nussler,A.K., Neuhaus,P., Hofmann,U., Eichelbaum,M., Schwab,M. and Zanger,U.M. (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 11, 399-415.
78. Hein,D.W., Grant,D.M. and Sim,E. (2000) Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics, 10, 291-292.
79. Malfatti,M.A. and Felton,J.S. (2001) N-glucuronidation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) and N-hydroxy-PhIP by specific human UDP-glucuronosyltransferases. Carcinogenesis, 22, 1087-1093.
80. Vaury,C., Laine,R., Noguiez,P., de Coppet,P., Jaulin,C., Praz,F., Pompon,D. and Gueret,M. (1995) Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res., 55, 5520-5523.
81. Loktionov,A., Watson,M.A., Gunter,M., Stebbings,W.S., Speakman,C.T. and Bingham,S.A. (2001) Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis, 22, 1053-1060.